Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Fixed Price Issue |
| Total Issue Size | ₹19.25 Cr |
| Reserved for Market Maker | ₹0.99 Cr |
| Net Issue Size | ₹19.25 Cr |
| Fresh Issue | ₹18.26 Cr |
| Face Value | ₹10 Per Equity Share |
| Issue Price | ₹35.00 per share |
| NSE Code | VIJAYPD |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Smart Horizon Capital Advisors... |
| Allotment Status | |
| DRHP |
| Final Prospectus |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 8,000 shares · Multiples of 4,000 shares
Incorporated in October 1971, Vijaypd Ceutical Limited distributes pharmaceutical products and consumer goods, offering a comprehensive range of services.
The company acts as representatives, dealers, agents, stockists, suppliers, traders, and packers.
The company serves the pharmaceutical and wellness industries, as well as the FMCG market, offering products like medicines (injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, liquid oral products), vitamins, hormones, enzymes, wellness tonics, serums, diagnostic test kits, personal care items (soaps, sanitizers, baby care), ayurvedic products, cosmetics, food products, dental products, and crude drugs.
As of Marc 31, 2025, the company serves over r 2,109 pharmacies, clinics, and nursing homes across four districts, covering 20 locations.
The company's distribution network connects with over 170 healthcare product manufacturers, providing access to more than 19,000 SKUs.
This product portfolio allows the company to meet customer needs while ensuring quality and reliability in pharmaceutical supply.
The company is a pharmaceutical distributor with FDA, FSSAI, and BMC certifications.
Competitive Strength:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding of capital expenditure requirements of the company towards the construction of Pharmaceutical API/ Intermediates and Chemicals manufacturing plant and purchase of machineries in MIDC-Shrirampur, Ahmednagar, Maharashtra | 10.83 |
| 2 | Repayment/prepayment of all or certain of the borrowings availed of by the Company | 5.10 |
| 3 | General Corporate Purposes | 0.74 |
| 4 | Issue Expenses | 2.58 |
| Total | 19.25 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 57.15 | 33.27 | 32.87 |
| Total Income | 107.59 | 54.34 | 50.59 |
| Profit After Tax | 4.80 | 1.65 | 0.18 |
| EBITDA | 8.59 | 4.87 | 1.32 |
| NET Worth | 32.17 | 1.00 | 4.93 |
| Reserves and Surplus | 18.14 | ||
| Total Borrowing | 21.77 | 30.04 | 25.56 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 28.91% |
| ROCE | 17.30% |
| Debt / Equity | 0.68% |
| RoNW | 14.91% |
| PAT Margin | 4.49% |
| EBITDA Margin | 8.04% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| Promoter Holding | 78.3% | 56.25% |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manager Fees including underwriting commission | 2.18 |
| 2 | Brokerage, selling, commission and upload fees | 0.01 |
| 3 | Registrar to the issue | 0.02 |
| 4 | Legal Advisors | 0.02 |
| 5 | Advertising and Marketing expenses | 0.03 |
| 6 | Regulators including stock exchanges | 0.04 |
| 7 | Printing and distribution of issue stationery | 0.01 |
| 8 | Others, if any (market making, depositories, industry report fees, marketing fees, secretarial, peer review etc.) | 0.28 |
| Total | 2.58 |
Last Updated on 07-Oct-2025 08:52:39
